Phibro Animal Health Corporation $PAHC Stock: Hennessy Advisors Inc. Reduces Position

Hennessy Advisors Inc. reduced its stake in Phibro Animal Health Corporation (NASDAQ:PAHC) by 8.9% during the 3rd quarter, Holdings Channel reports. The fund owned 202,000 shares of the company’s stock after selling 19,700 shares during the period. Hennessy Advisors Inc.’s holdings in Phibro Animal Health were worth $7,219,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Engineers Gate Manager LP grew its position in Phibro Animal Health by 112.8% during the second quarter. Engineers Gate Manager LP now owns 52,914 shares of the company’s stock valued at $1,662,000 after acquiring an additional 28,052 shares during the period. Cvfg LLC acquired a new stake in shares of Phibro Animal Health in the first quarter worth $2,962,000. Ranger Investment Management L.P. acquired a new stake in shares of Phibro Animal Health in the second quarter worth $9,182,000. Castleark Management LLC purchased a new position in shares of Phibro Animal Health in the 1st quarter valued at $7,904,000. Finally, Advisors Preferred LLC purchased a new position in shares of Phibro Animal Health in the 1st quarter valued at $2,931,000. Institutional investors and hedge funds own 99.34% of the company’s stock.

Phibro Animal Health Price Performance

Shares of NASDAQ:PAHC opened at $38.88 on Monday. The company has a market capitalization of $1.58 billion, a price-to-earnings ratio of 15.93 and a beta of 0.42. The company has a 50 day moving average of $36.99 and a two-hundred day moving average of $41.12. Phibro Animal Health Corporation has a 52-week low of $28.25 and a 52-week high of $60.08. The company has a quick ratio of 1.27, a current ratio of 2.96 and a debt-to-equity ratio of 1.84.

Phibro Animal Health (NASDAQ:PAHC) last posted its earnings results on Wednesday, August 26th. The company reported $0.85 EPS for the quarter, topping analysts’ consensus estimates of $0.71 by $0.14. The business had revenue of $396.75 million for the quarter, compared to analysts’ expectations of $381.18 million. Phibro Animal Health had a net margin of 6.57% and a return on equity of 37.86%. Phibro Animal Health has set its FY 2027 guidance at 3.410-3.590 EPS. As a group, analysts forecast that Phibro Animal Health Corporation will post 3.49 earnings per share for the current fiscal year.

Analyst Ratings Changes

PAHC has been the subject of a number of research reports. Zacks Research raised shares of Phibro Animal Health from a “hold” rating to a “strong-buy” rating in a research report on Friday, September 18th. Weiss Ratings reissued a “hold (c+)” rating on shares of Phibro Animal Health in a research report on Friday, September 11th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $47.67.

Phibro Animal Health Profile

Phibro Animal Health Corporation develops, manufactures and sells products designed to support the health, nutrition and productivity of food-producing animals. Its offerings include animal health products, vaccines, medicated feed additives, nutritional specialties and performance products used in livestock, poultry and aquaculture.

The company’s products are intended to help prevent and manage disease, improve animal well-being and support efficient food production. Phibro serves producers, veterinarians, feed manufacturers and distributors through a portfolio that includes pharmaceuticals, vaccines, mineral and nutritional supplements, and other feed and water solutions.

Phibro Animal Health markets its products internationally across a broad range of geographic regions, including North America, Latin America, Europe, Asia-Pacific and other global markets.